← All trials
NCT04372979
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2020
- Primary completion
- Oct 31, 2020
- Completion date
- May 31, 2021
- First posted
- May 4, 2020
- Last posted
- May 15, 2020
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Direction Centrale du Service de Santé des ArméesLead sponsor
- University of GrenobleCollaborator
- Direction Centrale du Service de Santé des ArméesStudy director
- Direction Centrale du Service de Santé des ArméesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.